Literature DB >> 28622593

Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression.

JianDe Gong1, XuFei Qi1, Yi Zhang1, YingCong Yu2, XiZhou Lin2, HongLiang Li3, YiRen Hu4.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) represents one of the most common malignancies worldwide. In two pubic long noncoding RNA (lncRNA) profiling studies of HCC, linc00462 was consistently upregulated. We analyzed the clinical significance and biological role of linc00462 in HCC.
METHODS: We performed quantitative real-time PCR analysis to determine the levels of linc00462 in HCC tissues from 49 patients. Functional analysis was performed in cell lines and in an animal model to support clinical findings.
RESULTS: Our data showed that linc00462 was significantly upregulated in HCC tissues compared with matched normal tissues. The knockdown of linc00462 in HCC cells resulted in a much less aggressive oncogenic phenotype, and linc00462 downregulation contribute to the inactivation of the PI3K/AKT signaling pathway.
CONCLUSIONS: linc00462 may be a potential therapeutic target in HCC.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Invasion; Long noncoding RNA; Proliferation; linc00462

Mesh:

Substances:

Year:  2017        PMID: 28622593     DOI: 10.1016/j.biopha.2017.06.004

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

Review 1.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

Review 2.  Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.

Authors:  Aya El Khodiry; Menna Afify; Hend M El Tayebi
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

3.  Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma.

Authors:  Zhicheng Yao; Changchang Jia; Yan Tai; Hao Liang; Zhaozhong Zhong; Zhiyong Xiong; Meihai Deng; Qi Zhang
Journal:  Aging (Albany NY)       Date:  2020-06-18       Impact factor: 5.682

Review 4.  Emerging roles of long non-coding RNAs in tumor metabolism.

Authors:  Hui Sun; Zhaohui Huang; Weiqi Sheng; Mi-Die Xu
Journal:  J Hematol Oncol       Date:  2018-08-22       Impact factor: 17.388

Review 5.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

6.  Comprehensive analysis of competing endogenous RNA network and 3-mRNA signature predicting survival in papillary renal cell cancer.

Authors:  Xin Zhu; Jianyu Tan; Zongjian Liang; Mi Zhou
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

7.  Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.

Authors:  Jie Cao; Lili Wu; Xin Lei; Keqing Shi; Liang Shi; Yifen Shi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway.

Authors:  Bin Zhou; Weidong Guo; Chuandong Sun; Bingyuan Zhang; Fang Zheng
Journal:  Cell Death Dis       Date:  2018-06-13       Impact factor: 8.469

9.  Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma.

Authors:  Li Sun; Yingying Su; Xiangxiang Liu; Mu Xu; Xiaoxiang Chen; Yefei Zhu; Zhirui Guo; Tingting Bai; Lin Dong; Chenchen Wei; Xiaoxiao Cai; Bangshun He; Yuqin Pan; Huiling Sun; Shukui Wang
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

10.  LINC00689 promotes prostate cancer progression via regulating miR-496/CTNNB1 to activate Wnt pathway.

Authors:  Liwei Meng; Zhonghai Li; Ye Chen; Deqian Liu; Zhaoxu Liu
Journal:  Cancer Cell Int       Date:  2020-06-05       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.